Is There a Tirzepatide Pill? Foundayo and Oral Options

No. As of November 2026, there is no FDA-approved tirzepatide pill. Tirzepatide, the medicine in Zepbound and Mounjaro, comes only as a once-weekly injection. Foundayo, the weight-loss pill Eli Lilly launched in 2026, is not tirzepatide: it contains orforglipron, a different GLP-1 medicine the FDA approved on April 1, 2026. Adults on its top dose lost an average of 11.1% of body weight over 72 weeks, and LillyDirect sells it for $149 to $299 a month. "Oral tirzepatide" drops, sprays and tablets sold online are not FDA-approved and have not been tested in human trials.

If you want tirzepatide itself, your options are Lilly's Zepbound (or Mounjaro, if you have type 2 diabetes) or compounded tirzepatide, a weekly injection that costs $120 a month, flat, at MaxLife but is not FDA-approved. If you won't inject at all, an FDA-approved pill such as Foundayo or the Wegovy pill is the better fit, and this guide explains how they compare.

Is There a Tirzepatide Pill?

No. The FDA's drug database lists two tirzepatide medicines, Zepbound and Mounjaro, and every version of both is a liquid injected under the skin: single-dose pens, KwikPens and vials (Drugs@FDA). Eli Lilly's medical information team says it directly: "Tirzepatide is not available in pill form for oral administration" (Lilly Medical).

The FDA said the same thing in May 2026, when it reviewed requests to make tirzepatide as tablets, capsules and under-the-tongue products: "no tirzepatide drug product is approved in these routes of administration" (Federal Register, May 1, 2026).

So there is no Zepbound pill or Mounjaro pill, and tirzepatide pills, tablets, drops or sprays sold online are not Zepbound or Mounjaro in another form. They are either a different drug, such as Foundayo, or a compounded or unapproved product. Our guide to tirzepatide vs Zepbound explains how compounded tirzepatide differs from the brand.

Why Doesn't Tirzepatide Come in Pill Form?

Tirzepatide is too large to be absorbed well from the gut. It is a peptide, a chain of amino acids, with a molecular weight of 4,813 daltons, and Lilly notes that medicines heavier than about 500 daltons generally are not absorbed when swallowed. Stomach acid and digestive enzymes also break peptides down before they can reach the blood.

The approved semaglutide pills show how hard this is. They contain an absorption enhancer called SNAC, and even so the body takes up only about 0.4% to 2% of each dose, according to the FDA's May 2026 notice. This is one reason the Wegovy pill's daily maintenance dose is 25 mg, while the weekly Wegovy injection is 2.4 mg.

Foundayo gets around the problem with a different kind of drug. Orforglipron is a small molecule, not a peptide, and about 77% of a dose reaches the bloodstream, according to the Foundayo prescribing information.

Is Foundayo a Tirzepatide Pill?

No. Foundayo is the brand name for orforglipron, a once-daily pill that activates the GLP-1 receptor only. Tirzepatide is a weekly injection that activates two receptors, GIP and GLP-1. Both are made by Eli Lilly, which is where much of the confusion comes from, but they are different drugs with different trial results.

Sources: Foundayo label, Zepbound label, SURMOUNT-1 and LillyDirect, as of November 2026.

The two share important safety rules. Both labels carry a boxed warning about thyroid C-cell tumors, neither is for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, and neither should be combined with another GLP-1 medicine. Never take Foundayo and tirzepatide together.

Foundayo vs Zepbound: Which Works Better for Weight Loss?

Zepbound produced nearly twice the average weight loss in its main trial, but the two drugs have never been tested against each other. The numbers come from separate 72-week trials in adults with obesity and without diabetes:

• Foundayo (ATTAIN-1): 3,127 adults lost an average of 7.4%, 8.3% and 11.1% of body weight on 5.5 mg, 9 mg and 17.2 mg, compared with 2.1% on placebo (label; trial in the New England Journal of Medicine).
• Zepbound (SURMOUNT-1): 2,539 adults lost an average of 15.0%, 19.5% and 20.9% on 5 mg, 10 mg and 15 mg, compared with 3.1% on placebo (SURMOUNT-1).

Side effects look alike in kind. Nausea affected 26% to 35% of people on Foundayo (10% on placebo) and 25% to 29% on Zepbound (8% on placebo), and both labels say most stomach side effects happened while the dose was being raised. In their own trials, 8% of people stopped Foundayo because of side effects (3% on placebo), and 4.8% to 6.7% stopped Zepbound (3.4% on placebo).

Can you switch from Zepbound to Foundayo? Some people do, often to stop injecting. In the Lilly-funded ATTAIN-MAINTAIN trial, adults who had lost weight on tirzepatide and then switched to orforglipron kept 74.7% of their weight loss after a year, compared with 49.2% for those switched to placebo. The trial had no group that stayed on injections, so it can't tell you whether switching costs some weight. Make that decision with your provider.

How Do You Take Foundayo?

You swallow one Foundayo tablet a day, at any time of day, with or without food. Unlike the semaglutide pills, it has no food or water rules: those must be taken on an empty stomach in the morning with no more than 4 ounces of water, followed by a 30-minute wait before eating.

The Foundayo label sets these rules:

• Dose steps: start at 0.8 mg for at least 30 days, then 2.5 mg for at least 30 days, then 5.5 mg. Your provider may raise it to 9 mg, 14.5 mg or 17.2 mg, at least 30 days apart, based on your response and side effects. The most is 17.2 mg a day.
• Tablets: swallow them whole; don't split, crush or chew them, and never take more than one a day.
• Missed dose: take it as soon as you can, and don't double up. If you miss 7 or more doses in a row, your provider will restart the dose steps at a lower dose.
• Other medicines: some medicines change orforglipron levels, such as the antibiotic clarithromycin (which raises them) and the seizure medicine carbamazepine (which lowers them). With a strong CYP3A4 inhibitor, the most you can take is 9 mg. Give your provider your full medicine list.
• Birth control pills: the label advises switching to a non-oral method, or adding a barrier method, for 30 days after you start and after each dose increase.
• Pregnancy: stop Foundayo if you become pregnant.

Talk to your provider about your own history before you start, including any pancreatitis, gallbladder disease or kidney problems.

How Much Does Foundayo Cost?

Because there is no tirzepatide pill, a "tirzepatide pill price" you see online is either for Foundayo, a different drug, or for an unapproved product. As of November 2026, LillyDirect sells Foundayo for $149 to $299 a month without insurance (a month is 30 tablets):

Prices are from LillyDirect and its terms. At 9 mg or more, Foundayo costs $299 a month, about $3,600 for 12 months if Lilly keeps that price after December 31, 2026.

Insurance can lower that. With commercial coverage for Foundayo, Lilly's savings card can bring it to as little as $25 a month. Since July 1, 2026, eligible Medicare Part D members can get Foundayo, the Wegovy pill or pen, or the Zepbound KwikPen for a $50 copay through the Medicare GLP-1 Bridge, which runs through December 31, 2027 and has BMI and diagnosis rules. Our guide to weight loss drugs covered by insurance explains prior authorization and appeals.

For comparison, Zepbound costs $299 to $449 per 28 days through LillyDirect, and our tirzepatide cost guide adds up a full year for each route.

What Other GLP-1 Pills Are There?

As of November 2026, the FDA-approved GLP-1 pills are Foundayo, the Wegovy pill and the oral semaglutide for diabetes sold as Ozempic tablets (replacing Rybelsus). Only the first two are for weight loss:

The Wegovy pill was approved on December 22, 2025 (Novo Nordisk). In its 64-week trial, adults on the 25 mg dose lost an average of 13.6% of body weight, compared with 2.4% on placebo (Wegovy label). You take it each morning on an empty stomach with up to 4 ounces of water, then wait 30 minutes before eating, drinking or taking other pills. NovoCare lists $149 for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg. Our tirzepatide vs Wegovy comparison covers how semaglutide and tirzepatide differ. For results, side effects and cost side by side, see Wegovy pill vs injection.

Is there an Ozempic pill? Yes, for type 2 diabetes. Oral semaglutide for diabetes is sold as Ozempic tablets, which Novo Nordisk says are replacing Rybelsus (label). Neither is approved for weight loss, and their doses can't be swapped mg for mg.

If you'd rather pay cash for semaglutide, MaxLife offers compounded semaglutide injections at $89 a month, flat. Like compounded tirzepatide, it is not FDA-approved and is not a pill.

What Is "Oral Tirzepatide"? Drops, Sprays and Tablets Sold Online

"Oral tirzepatide" is a sales name, not an approved medicine. It covers products that claim to contain tirzepatide in another form: drops or dissolving tablets placed under the tongue, troches, capsules, and even nasal sprays. Some are made by compounding pharmacies for a prescription; others are sold as "research" chemicals. None is FDA-approved.

Compounded tirzepatide is prepared by a licensed pharmacy for one patient's prescription and is not FDA-approved, which means the FDA hasn't reviewed it for safety, effectiveness or quality. That is true of compounded injections and compounded drops alike.

The FDA has been direct about these forms:

• Not approved, not needed. In its May 2026 notice, the FDA said no tirzepatide product is approved for oral, under-the-tongue or inside-the-cheek use. It also said it "has not identified a basis to conclude" that a compounded oral, buccal or sublingual product meets a medical need the approved injections can't, and that its test is clinical need, "not 'preference.'" The finding is part of a proposal about what outsourcing facilities may compound, still open as of November 2026.
• "Research use" products. The FDA warns that tirzepatide sold "for research purposes" or "not for human consumption" is of unknown quality and may be harmful.
• Sales claims. Since February 2026, the FDA has said that sellers can't call compounded products generic, "the same as" an FDA-approved drug or "clinically proven." A seller that describes its drops that way is making a claim the FDA rejects.

MaxLife doesn't sell oral tirzepatide in any form.

Does Oral Tirzepatide Work?

There is no evidence that it does. As of November 2026, ClinicalTrials.gov lists no human study of sublingual or nasal tirzepatide, and the only published work on tirzepatide tablets is laboratory research, including a 2026 tablet formulation tested in rats. No public data show how much tirzepatide from a drop or tablet reaches the blood. Given tirzepatide's size, and how little of even an enhanced semaglutide pill gets absorbed, there is good reason to doubt that a drop delivers a useful dose.

That puts "oral tirzepatide reviews" in context. They are personal reports about unapproved products, often with diet changes at the same time, and they can't tell you what was in the bottle or how much of it you absorbed. The weight-loss results quoted for tirzepatide come from trials of Zepbound and Mounjaro injections. They have not been shown for compounded tirzepatide, and not for drops or tablets either.

If needles are the reason you're looking, an FDA-approved pill with trial data, such as Foundayo or the Wegovy pill, is the safer route.

Pill or Weekly Injection: Which Is Right for You?

The best choice depends on what matters most to you: avoiding needles, the size of the expected effect, cost or coverage. Here is an honest way to sort it out with your provider.

A daily pill may suit you if:

• you won't or can't inject, even once a week;
• your plan or the Medicare GLP-1 Bridge covers Foundayo or the Wegovy pill;
• you prefer a daily routine to a weekly one.

A weekly injection may suit you if:

• you want tirzepatide itself (Zepbound produced more average weight loss in its trials than either pill did in theirs);
• you'd rather think about your medicine once a week than every day;
• you are paying cash and want tirzepatide at a lower monthly price.

For cash-pay tirzepatide, MaxLife offers compounded tirzepatide as a weekly injection for $120 a month, flat, billed every 3 months ($360), with no membership fee. The price is all-inclusive: a licensed provider's review and follow-up, the medicine if prescribed, supplies and free expedited shipping. Higher doses are available when a provider prescribes them, at the same price. MaxLife is a telehealth patient management platform, not a pharmacy: independent licensed providers decide whether a prescription is right for you, and licensed partner pharmacies prepare and dispense it. Compounded tirzepatide usually comes in a multi-dose vial, and the FDA has noted that compounded vial concentrations may differ from the brand's, so follow the written instructions for your vial. To compare total costs across programs, see our cheapest tirzepatide online guide and our comparison of 24 online tirzepatide providers.

Be clear about the trade: compounded tirzepatide costs less than Zepbound, but you give up FDA approval and insurance coverage. MaxLife doesn't offer pills, so if a pill is what you want, ask your own doctor about Foundayo or the Wegovy pill, or use LillyDirect or NovoCare.

Conclusion

There is no tirzepatide pill. Zepbound and Mounjaro are weekly injections, and the drops, sprays and tablets sold as "oral tirzepatide" are not FDA-approved and have no human trial data. Foundayo is a real, FDA-approved weight-loss pill, but it is orforglipron, not tirzepatide, and its average weight loss in trials was smaller than Zepbound's. If you want an approved pill, ask about Foundayo or the Wegovy pill. If you want tirzepatide, choose a weekly injection: Zepbound from Lilly or compounded tirzepatide, a lower-cost cash route that is not FDA-approved.